Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had its target price trimmed by Stifel Nicolaus from $68.00 to $36.00 in a report published on Thursday morning. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
Several other research firms have also issued reports on ALNY. Needham & Company LLC restated a buy rating and set a $152.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, August 5th. Cowen and Company restated a buy rating and set a $150.00 price target on shares of Alnylam Pharmaceuticals in a report on Sunday, August 7th. Jefferies Group set a $86.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, September 28th. Janney Montgomery Scott assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 28th. They set a neutral rating and a $74.00 price target for the company. Finally, Goldman Sachs Group Inc. reiterated a neutral rating and issued a $65.00 price objective (up previously from $63.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, August 10th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $79.50.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.83 on Thursday. The firm’s 50-day moving average is $68.44 and its 200 day moving average is $65.73. The company’s market capitalization is $2.99 billion. Alnylam Pharmaceuticals has a 52-week low of $33.16 and a 52-week high of $110.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm earned $8.70 million during the quarter, compared to analyst estimates of $8.09 million. During the same quarter last year, the business earned ($0.85) EPS. The company’s revenue was up .2% compared to the same quarter last year. On average, equities research analysts anticipate that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current year.
In other news, CEO John Maraganore sold 30,151 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the sale, the chief executive officer now directly owns 148,465 shares in the company, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.00% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Aperio Group LLC boosted its stake in Alnylam Pharmaceuticals by 129.9% in the first quarter. Aperio Group LLC now owns 14,741 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 8,328 shares during the last quarter. Pacad Investment Ltd. acquired a new stake in Alnylam Pharmaceuticals during the first quarter worth approximately $490,000. BlackRock Inc. boosted its stake in Alnylam Pharmaceuticals by 29.7% in the first quarter. BlackRock Inc. now owns 69,736 shares of the biopharmaceutical company’s stock worth $4,377,000 after buying an additional 15,965 shares during the last quarter. BlackRock Group LTD boosted its stake in Alnylam Pharmaceuticals by 21.9% in the first quarter. BlackRock Group LTD now owns 519,834 shares of the biopharmaceutical company’s stock worth $32,630,000 after buying an additional 93,450 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its stake in Alnylam Pharmaceuticals by 6.5% in the first quarter. BlackRock Fund Advisors now owns 1,838,376 shares of the biopharmaceutical company’s stock worth $115,395,000 after buying an additional 112,252 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.